drugset / Trial / NCT04764383

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383

Phase 2 Withdrawn University of Miami
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this research study is to identify a way to improve the feeling of exhaustion that patients might experience because of Multiple Sclerosis (MS).

Timeline

Start
2022-01-01
Primary completion
2022-10-30
Completion
2022-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HISTIDINE Small molecule 1000 mg Oral
Subject Lodosyn Unknown 50 mg Oral

Indications